Refine your results

to


Search

Sonepcizumab shows promise for metastatic renal cell carcinoma

Show Citation

November 2, 2016

AUTHORS:

Pal SK, Drabkin HA, Reeves JA, Hainsworth JD, Hazel SE, Paggiarino DA, Wojciak J, Woodnutt G, Bhatt RS.

BACKGROUND:

Upregulation of sphingosine-1-phosphate (S1P) may mediate resistance to vascular endothelial growth factor (VEGF)-directed therapies and inhibit antitumor immunity. Antagonism of S1P in preclinical models appears to overcome this resistance. In this phase 2 study the authors assessed the activity of sonepcizumab a first-in-class inhibitor of S1P, in patients with metastatic renal cell carcinoma with a history of prior VEGF-directed therapy.

Advertisement
Advertisement